Akzo Nobel shares nosedive 15% as Imperial Chemical likely offloads 48.8 lakh shares via block deal

Shares of Akzo Nobel India tumbled 15% to their intraday low of Rs 3,080 on the BSE on Wednesday, December 17, amid reports that Imperial Chemical Industries likely sold 48.8 lakh shares of the company via a block deal.

According to previous CNBC TV-18 reports, Imperial Chemical Industries intended to offload up to a 9% stake in the company, taking the total offer size for the stake sale to approximately Rs 1,290.6 crore.

The block deal was reportedly set to be conducted at a floor price of Rs 3,150 per share, representing a 13.1% discount to Akzo Nobel India's previous closing price.


On Tuesday, the shares of Akzo Nobel India closed flat with marginal losses at Rs 3,623.95 on the BSE.

Akzo Nobel Q2 results

Akzo Nobel India Ltd. reported a sharp rise in its quarterly net profit, with Profit After Tax (PAT) including exceptional items for Q2FY2025-26 standing at Rs 1,682.7 crore, a substantial 2119.8% increase from Rs 75.8 crore in the year-ago period.

The company’s revenue from operations for the quarter, excluding its divested Powder Coatings and IRC businesses, came in at Rs 834.9 crore, registering a 1.5% decline from Rs 847.7 crore in the corresponding quarter last year.

In terms of operating performance, Earnings Before Interest and Tax (EBIT) for Q2FY26 was reported at Rs 92.3 crore, down 2.4% from Rs 94.5 crore recorded in Q2FY25.

Share price history of Akzo Nobel

Over the last one year, the shares of Akzo Nobel have registered a modest gain of 2.66%, reflecting a relatively stable performance. On a year-to-date (YTD) basis, it has inched up by 1.82%, suggesting a slow but steady move in 2025 so far.

Looking at the six-month performance, the stock has seen a more noticeable rise of 11.68%, indicating stronger momentum in the recent half-year. In the last three months, the gains stood at 7.12%, while the one-month return came in at a healthy 7.89%, showing a pickup in price action in the short term.

Also read: Vijay Kedia buys 9 lakh shares of SME stock Mahamaya Lifesciences in Rs 12.5 crore block deal

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)